T he Human Genome Project (HGP)
has become highly controversial due to the entrance of commercial competition. Recent literature explores such concerns as patenting, secrecy, excessive duplication of efforts, and focus on profits rather than quality of research [1] [2] [3] .
To assess the opinions of human geneticists on these issues, we mailed questionnaires to the 3,632 scientist members of the American Society of Human Genetics residing in the U.S. (Table 1) . We received 1,229 anonymously completed questionnaires that met our criteria for eligibility (only scientists who have at some point engaged in human genetics research). The relatively high response rate of 44% indicates that the issues are of interest to many researchers.
Benefits and disadvantages of commercialization. We inquired whether respondents agreed or disagreed with various benefits and disadvantages of commercial competition with the HGP that have been discussed in recent articles. Overall, there is substantial agreement with benefits as well as disadvantages (Table 2 ; instruction was to check all that apply). Notably, 90% of the respondents see excessive patenting as a problem; this issue does not seem to be influenced by employment, as 86% of industry scientists agree with this view.
What should be patentable? Only 2% of respondents say any DNA sequence, and 18% say only full-length genes where the entire DNA sequence is known and the function is determined; however, a clear majority (75%) disapprove of patenting DNA altogether. Employment does seem to influence these results: 77% of academics and 78% of government scientists disapprove of patenting DNA, whereas only 61% of industry scientists disapprove (still, however, a majority).
Should the publicly funded HGP patent gene sequences? One might expect greater approval of gene sequence patenting by the government sector, as the public sector is seen to defend genes from exclusive commercialization. By contrast, a majority of almost 3:1 (62% versus 21%) thinks the HGP should not patent results. Furthermore, almost half (47%) feel patenting "inhibits and delays biomedical research," compared with those who think that patenting "is needed to encourage and protect new biomedical research" (27%).
Should NIH reinstate its rule requiring commercial partners to charge 'reasonable' prices for pharmaceutical products developed that were based on NIH research? 69% said yes, and 12%, no.
If there is patenting of sequences, should it be broad or narrow? As one might expect, a large majority (76%) favor narrow patent protection (limited to the native DNA or protein sequence discovered); only 6% prefer broad proprietary rights for DNA sequences and any potential variants; 18% are not sure.
To what extent has human-DNA patenting limited scientists' research, and how does this affect their outlook on DNA patenting? Approximately half (49%) say patenting has at some time limited their research (7% frequently, 26% once in a while, 16% hardly ever), whereas almost half (46%) say it never has. The patenting of human DNA is unpopular regardless of this factor: almost threequarters (74%) of those frequently or sometimes affected disapprove of patenting human DNA; however, essentially the same proportion (75%) of those who were never or hardly ever hindered by a patent also disapproved. 
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